
Report sees strong year ahead for life sciences IPOs despite headwinds
The report, by law firm WSGR, noted an almost twofold increase in life sciences IPOs - especially biotech - and a greater number priced at $250 million or more.
The report, by law firm WSGR, noted an almost twofold increase in life sciences IPOs - especially biotech - and a greater number priced at $250 million or more.
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
As Lisa Suennen said about this year's JP Morgan Healthcare Conference, "There was a lot of optimism about the convergence of biotech, life sciences and health IT, but also there was a sense of foreboding that the party is over in some of these areas."
This week we will be looking back at 2016 JP Morgan Healthcare Conference: what was said, the big news and what it means for the business of healthcare going forward.